B cells temporarily regain stem-like flexibility, increasing risk of lymphoma formation

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Canadian Patent No. 3043594, entitled “Method of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity,” provides Longeveron with patent rights in Canada through 2037.

GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients

ATLANTA, GA - December 15, 2025 ( NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today announced the ...
Morningstar

Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate

Research published in Science Advances indicates that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective with minimal reactogenicity Blue Lake ...
BioSpace

Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate

Research published in Science Advances indicates that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective with minimal reactogenicity ATHENS, Ga. & ...
eLife

SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated nef variant

Yamamoto and Matano provide convincing evidence that a G63E/R CD8+ T-cell escape mutation in the accessory viral protein Nef promote the induction of neutralizing antibody (nAb) responses in rhesus ...
Business Wire

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...
C&EN

A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants

State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People’s Republic of China University of Chinese Academy of ...
The Lancet

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study

aViro-Immunology Research Unit, Department of Infectious Diseases, Section 8632, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark bDepartment of Haematology, ...
New Atlas

Single-dose inhaled dry powder vaccine may replace arm jabs

Researchers have developed a single-dose powdered vaccine that is inhaled directly into the lungs to produce an effective immune response. The vaccine can deliver multiple antigens, meaning one dose ...
SciTech Daily

Puff of Protection: China’s Major Leap in Inhalable Vaccine Technology

A new “nano-micro composite” delivery concept for inhaled vaccine: it combines biodegradable microcapsules with protein nanoparticles displaying multiple antigens, thus induces a broad-spectrum immune ...